Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30061726 | 0.95 | USP7 (0.91) | USP7 | |
| SCHEMBL20864451 | 0.95 | USP7 (0.91) | USP7 | |
| SCHEMBL20864351 | 0.92 | USP7 (0.85) | USP7 | |
| SCHEMBL20864296 | 0.91 | USP7 (0.84) | USP7 | |
| SCHEMBL20864340 | 0.91 | USP7 (0.84) | USP7 | |
| SCHEMBL20864300 | 0.91 | USP7 (0.83) | USP7 | |
| SCHEMBL30063698 | 0.91 | USP7 (0.83) | USP7 | |
| SCHEMBL20864305 | 0.91 | USP7 (0.82) | USP7 | |
| SCHEMBL20864318 | 0.91 | USP7 (0.82) | USP7 | |
| SCHEMBL20864353 | 0.91 | USP7 (0.82) | USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117925814-A | Use of USP-7 in the manufacture of a product for diagnosis or risk assessment of diabetic heart disease | 广东药科大学 | 2024-04-26 | — | — | CN | claimed |
| US-9546150-B2 | Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2017-01-17 | — | — | US | claimed |
| EP-2751092-B1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2016-07-27 | — | — | EP | claimed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | claimed |
| EP-2751092-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2014-07-09 | — | — | EP | claimed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | claimed |
| EP-2565186-A1 | Selective and reversible inhibitors of ubiquitin specific protease 7 | Hybrigenics S.A. (FR) | 2013-03-06 | — | — | EP | claimed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| CN-118021824-B | Medicine for resisting Marek's disease virus and application of dandelion sterol or ferulic acid in preparation of medicine by combination | 吉林大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-118021772-B | Anti-Marek's disease virus medicine, resveratrol or chlorogenic acid and application of resveratrol or chlorogenic acid in combination in preparation of medicine | 吉林大学 | 2024-11-08 | — | — | CN | disclosed |
| CN-118078824-B | Anti-Marek's disease virus medicine and application of RA190 or glycyrrhizic acid and combined use thereof in preparation of medicine | 吉林大学 | 2024-11-08 | — | — | CN | disclosed |
| CN-117925814-B | Use of USP-7 in the manufacture of a product for diagnosis or risk assessment of diabetic heart disease | 广东药科大学 | 2024-08-02 | — | — | CN | disclosed |
| US-20240203555-A1 | METHODS AND SYSTEMS FOR THERAPY MONITORING AND TRIAL DESIGN | SCIPHER MEDICINE CORP (US) | 2024-06-20 | — | — | US | disclosed |
| US-9546150-B2 | Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2017-01-17 | — | — | US | disclosed |
| EP-2751092-B1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2016-07-27 | — | — | EP | disclosed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | disclosed |
| EP-2565186-A1 | Selective and reversible inhibitors of ubiquitin specific protease 7 | Hybrigenics S.A. (FR) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | USP7 1137/4885 |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | USP7, UBA7, SENP7 | USP7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.